FIGURE 3 - available via license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Content may be subject to copyright.
Output signal after signal processing and features generated for analysis. (A) Maximum magnitude (24hMagn) is indicated by the arrow, absolute area under the monitoring curve (24hArea) for 24-hour fluctuations appears in grey; (B) Maximum magnitude (w4Magn) is indicated by the arrow, absolute area under the subsignal from the decomposition over the wavelet w 4 (w4Area) for fluctuations of frequency period ranging from 60 to 220 minutes appears in grey.
Source publication
Purpose:
The purpose of this study was to compare 24-hour intraocular pressure (IOP) related fluctuations monitoring between 2 groups of visual field progression rates in patients with open angle glaucoma (OAG).
Methods:
Cross-sectional study performed at Bordeaux University Hospital. Twenty-four-hour monitoring was performed using a contact len...
Contexts in source publication
Context 1
... belongings to the first set were calculated on the sub-signal that lied in the frequency range of diurnal fluctuations (cumulative decomposition from W 4 to W 10 ). Two features were computed (Fig. 3A): -The diurnal amplitude, which is the highest voltage magnitude of the curve over the 24-hour period of the monitoring (called h24Magn, expressed in Volt [V]). -The absolute area under the monitoring curve (h24Area, expressed in Volt.second ...
Context 2
... related to more rapid fluctuations (ultradian rhythm) were computed on the two sub-signals obtained from the decomposition on w 4 and w 5 corresponding to fluctuation of period 60 to 220 minutes, and 120 to 500 minutes, respectively. Two features per decomposition were computed ( Fig. ...
Citations
... Several studies have investigated the diagnostic performance of contact lens sensors in detecting glaucoma progression by monitoring IOP fluctuations. Gaboriau et al., reported that contact lens sensors showed high diagnostic performance in detecting glaucoma progression compared to standard methods of IOP measurement [22]. Similarly, Tan et al., revealed that ultra-short-term IOP fluctuations detected by contact lens sensors were associated with disease progression in primary angle-closure glaucoma patients [23]. ...
... Characteristics of CLs may serve as additional risk factors in clinical practice and may help to adjust the treatment strategy at an earlier stage. 102 New research shows that tear glucose levels are linked to blood glucose levels and tears can be collected and analyzed steadily to determine diabetes and its progress. 103 As a noninvasive, continuous, and real-time blood glucose monitoring, recent extensive research work has been devoted to the development of smart contact lenses with this function. ...
Unlike conventional glasses, corneal contact lenses (CLs) can directly contact the surface of the tear film through the application of biopolymer materials, to achieve therapeutic and cosmetic purposes. Since the advent of polymethylmethacrylate, a material that has gained widespread use and attention, statistically, there are now more than 150 × 106 people around the world who wear corneal contact lenses. However, the associated complications caused by the interaction of contact lenses with the ocular surface, tear film, endogenous and environmental microorganisms, and components of the solution affect nearly one-third of the wearer population. The application of corneal contact lenses in correcting vision and myopia control has been widely recognized. With the development of related materials, corneal contact lenses are applied to the treatment of ocular surface diseases, including corneal bandage lenses, drug-loaded corneal contact lenses, biosensors, and other new products, while minimizing the side effects associated with CL wear. This paper summarized the development history and material properties of CLs, focused on the current main clinical applications and mechanisms, as well as clarified the possible complications in wearing therapeutic contact lenses and the direction for improvement in the future.
... Many aspects of these novel therapeutic modalities have been recently reviewed and discussed and cover the potential therapeutic effects of AQH-derived and/or retinal organoid-derived extracellular vesicles and their cargos, such as miRNAs and trophic factors, and even the use of nutraceutical approaches to curb vision loss [236][237][238][239][240][241][242][243][244][245][246][247][248][249][250]. Likewise, to aid in the early detection and diagnosis of OHT, OAG, and other degenerative retinal and brain diseases, several novel tools are being evaluated and have advanced to different degrees of predictability, reliability, and acceptability by the scientific community [251][252][253][254][255][256]. We hope that many of the latter diagnostic technologies and therapeutic modalities will enter clinical trials and proceed towards health authority approvals in the near future. ...
Serious vision loss occurs in patients affected by chronically raised intraocular pressure (IOP), a characteristic of many forms of glaucoma where damage to the optic nerve components causes progressive degeneration of retinal and brain neurons involved in visual perception. While many risk factors abound and have been validated for this glaucomatous optic neuropathy (GON), the major one is ocular hypertension (OHT), which results from the accumulation of excess aqueous humor (AQH) fluid in the anterior chamber of the eye. Millions around the world suffer from this asymptomatic and progressive degenerative eye disease. Since clinical evidence has revealed a strong correlation between the reduction in elevated IOP/OHT and GON progression, many drugs, devices, and surgical techniques have been developed to lower and control IOP. The constant quest for new pharmaceuticals and other modalities with superior therapeutic indices has recently yielded health authority-approved novel drugs with unique pharmacological signatures and mechanism(s) of action and AQH drainage microdevices for effectively and durably treating OHT. A unique nitric oxide-donating conjugate of latanoprost, an FP-receptor prostaglandin (PG; latanoprostene bunod), new rho kinase inhibitors (ripasudil; netarsudil), a novel non-PG EP2-receptor-selective agonist (omidenepag isopropyl), and a form of FP-receptor PG in a slow-release intracameral implant (Durysta) represent the additions to the pharmaceutical toolchest to mitigate the ravages of OHT. Despite these advances, early diagnosis of OHT and glaucoma still lags behind and would benefit from further concerted effort and attention.
Glaucoma, marked by its intricate association with intraocular pressure (IOP), stands as a predominant cause of non-reversible vision loss. In this review, the physiological relevance of IOP is detailed, alongside its potential pathological consequences. The review further delves into innovative engineering solutions for IOP monitoring, highlighting the latest advancements in wearable and implantable sensors and their potential in enhancing glaucoma management. These technological innovations are interwoven with clinical practice, underscoring their real-world applications, patient-centered strategies, and the prospects for future development in IOP control. By synthesizing theoretical concepts, technological innovations, and practical clinical insights, this review contributes a cohesive and comprehensive perspective on the IOP biosensor's role in glaucoma, serving as a reference for ophthalmological researchers, clinicians, and professionals.
